Ketamine America
- Ketamine Therapy
- Migraine Treatment
- Lyme Disease Treatment
Read the Ketamine Therapy guide for the educational context behind this treatment category.
Mesa, AZ
Ketamine therapy in Mesa is delivered through psychiatry-led clinics, anesthesia-run infusion centers, and ketamine-assisted psychotherapy practices, with hospital referrals often tied to Banner Desert Medical Center and Mountain Vista Medical Center. Demand reflects a large East Valley family and retiree population and an active local market for treatment-resistant depression, PTSD, and chronic pain.
The strongest evidence supports intranasal esketamine (Spravato, FDA-approved for treatment-resistant depression) and intravenous racemic ketamine (off-label, substantial supporting evidence). Clinics in Mesa, Arizona also offer intramuscular, sublingual, and at-home oral lozenge protocols, with weaker evidence and variable safety oversight. Arizona's relatively permissive regenerative medicine climate shapes which clinics can operate as cash-pay versus insurance-eligible.
With ketamine clinics on Regenerated.com in Mesa, patients can compare whether the clinic offers psychiatric evaluation, anesthesia monitoring during infusion, and structured preparation and integration.
Regulatory context
Ketamine is a DEA Schedule III controlled substance, FDA-approved as a dissociative anesthetic and used off-label for treatment-resistant depression, PTSD, and chronic pain. The FDA approved esketamine (Spravato) in 2019 for treatment-resistant depression under a Risk Evaluation and Mitigation Strategy (REMS) program that requires in-office administration at certified sites. MDMA-assisted therapy remains Schedule I; the FDA issued a Complete Response Letter in August 2024 to Lykos Therapeutics on its MDMA new drug application. Psilocybin is Schedule I and holds FDA Breakthrough Therapy designation through sponsors such as Compass Pathways and Usona, but has not received FDA approval. Oregon Measure 109 (passed 2020, operational 2023) created a state psilocybin service center framework, and Colorado Proposition 122 (2022) authorized regulated healing centers.
Arizona enforces federal DEA scheduling and has not decriminalized psilocybin or MDMA. The Arizona Medical Board and Arizona Board of Osteopathic Examiners oversee prescribing conduct. DEA enforcement on ketamine clinics focuses on compounding sources, diversion, and billing fraud. Ryan Haight Act rules apply to telehealth ketamine prescriptions, with DEA flexibilities extended through 2025.
Explore nearby
Available here
Explore statewide
Ketamine Therapy in ArizonaNationwide
Ketamine Therapy clinics across the US